Claims for Patent: 9,213,038

Summary for Patent: 9,213,038

Title:	Early marker of proteinuria in patients treated with an anti-VEGF treatment
Abstract:	This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.
Inventor(s):	Garovic; Vesna D. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	13/898,124
Patent Claims:	1. A method for using an anti-VEGF therapy, without inducing proteinuria, to treat cancer in a human having cancer, wherein said method comprises: (a) administering an initial dose of said anti-VEGF therapy to said human to treat said cancer, (b) obtaining a urine sample from said human receiving said anti-VEGF therapy, (c) contacting said urine sample with an antibody that binds to podocytes or polypeptides expressed by podocytes to form an antigen-antibody complex, if podoycytes or polypeptides expressed by podocytes are present in said sample, (d) detecting, by flow cytometry, the presence of said antigen-antibody complex, thereby identifying said human as being at risk of developing proteinuria, if said complex is detected and (e) administering a subsequent dose of said anti-VEGF therapy to said human who does not have proteinuria, but in whom the antigen-antibody complex has been detected, wherein said subsequent dose is at least 30 percent lower than said initial dose. 2. The method of claim 1, wherein said method is a method for treating a human with said anti-VEGF therapy, wherein said method comprises administering an initial dose of said anti-VEGF therapy, and wherein said method comprises administering a subsequent dose of said anti-VEGF therapy. 3. The method of claim 2, wherein said anti-VEGF therapy is selected from the group consisting of a bevacizumab therapy, a sunitinib therapy, and a sorafenib therapy. 4. The method of claim 1, wherein said human is a non-pregnant human. 5. The method of claim 1, wherein said administering said initial dose comprises administering between 5 and 15 mg of said anti-VEGF therapy per kg of body weight of said human per day once every week, once every two weeks, or once every three weeks. 6. The method of claim 1, wherein said urine sample is obtained from said human within at least three days of administration of said initial dose. 7. The method of claim 1, wherein said antibody is an anti-podocin antibody.

Details for Patent 9,213,038

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2029-12-21